Literature DB >> 7192215

A phase II study of Cis-platinum for recurrent corpus cancer.

C Tropé, H Grundsell, J E Johnsson, E Cavallin-Ståhl.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7192215     DOI： 10.1016/0014-2964(80)90248-0

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN： 0014-2964            Impact factor:   9.162


× No keyword cloud information.
  2 in total

1.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle
Journal:  Gynecol Oncol       Date:  2013-02-21       Impact factor: 5.482

2.  Gefitinib enhances sensitivity of endometrial cancer cells to progestin therapy via dual-specificity phosphatase 1.

Authors:  Yuan Yang; Jingyi Zhou; Xiaoping Li; Lijun Zhao; Yuan Cheng; Yanying Lin; Jiaqi Wang; Lihui Wei; Yafeng Dong; Jianliu Wang
Journal:  Oncotarget       Date:  2017-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.